Expanded CRO services to support biotechs and mid-sized pharma companies across trials in more than 40 countries
Ghent, September 23, 2020: Europital – a globally-focused full service CRO serving small and mid-tier innovators – announces a significant expansion as it launches new capabilities across project management, clinical monitoring, biostatistics, pharmacovigilance, regulatory affairs and data management, in addition to its existing services of Medical Affairs and Medical Writing. The expanded clinical research offering will see Europital support clients as a full service CRO in over 40 countries from IND through to commercial launch.
“We are delighted to announce that we can now provide a full, 360-degree CRO service to innovators in the pharmaceutical, biotechnology and medical devices sectors. Europital has seen a robust expansion in the last few years, and we have been steadily preparing to launch full service capabilities.
“It’s no secret, there is a large gap in the CRO industry for these small innovators; what they need is a science-driven CRO that will support them closely with an experienced senior team but combined with a global trial network. We’re very excited to be able to further support our current partners and many of the new innovators bringing vital therapies to patients,” commented Dr. Mohamed El Malt, Chief Medical Officer of Europital.
Europital has regional offices in Belgium, Hungary and the UK and their customers are based in both Europe and the USA. Innovators developing therapies for oncology, infectious diseases, inflammatory and autoimmune diseases will be the major beneficiaries of Europital’s multi-functional and operational capabilities. Sponsors who will particularly benefit are those that require a full range of CRO services for complex molecules and trial designs that necessitate senior medical and scientific oversight.
In addition to its regional offices in Europe, Europital has built a global network of trusted partners over the last 10 years with local operational expertise and preferential supply trial site agreements in the USA, Canada, Russia, India, the Middle East and North Africa and Australia.
“The difference we bring to sponsors is that our senior teams stay with trials from contract to commercialization – you get the same, experienced team throughout the lifecycle of your development plan. As a science-based CRO we provide in-depth medical knowledge and industry knowhow, with a track record of outstanding delivery.
“The decision to launch as a full-service CRO reflects the many requests we have had from our clients over the years to work on additional aspects of their clinical trials, but the services for which we did not have in-house. Now we are able to support them throughout the whole trial process. Our goal is to continue building our partnerships to become the leading science-based CRO for small to mid-sized pharma and biotech companies,” added Dr. El Malt.
